State-based Reform
-
340B, Biosimilars, Caught my eye, Employers, Importation, Obesity, Pharmacy Benefit Managers, State-based ReformCaught my eye — 03/15/24
Read more: Caught my eye — 03/15/24It was one of those rare weeks in Washington, DC where the weather was just perfect. I mean not if you suffer from allergies, but for everyone else. Same Same. Last week we had the State of the Union, this week we had the President’s Budget release. For what it is worth, the budget is…
-
Caught my eye — 2/23/24
Read more: Caught my eye — 2/23/24Gross to Net, a Saga. As soon as I saw Adam Fein’s Drug Channels article on Gross to Net in Part D redesign, I knew it would throw off my day. It was just catchy enough to cause a buzz and get the attention of Heads of Market Access at pharmaceutical companies and start the…
-
Caught my eye, CMMI, Drug Prices, Inflation Reduction Act, Insulin, Medicare Negotiation, State-based ReformCaught my eye — 2/2/24
Read more: Caught my eye — 2/2/24It is a dumb bucket list thing but one day I will go experience the Groundhog Day festivities. Dream big, I know. Cell and Gene Update. This week the Centers for Medicare and Medicaid Innovation (CMMI) released the Cell and Gene Therapy (CGT) Access model which will initially focus on sickle cell disease. It is…
-
340B, Alzheimer’s, Caught my eye, Drug Prices, Drug shortages, Medicare Advantage, State-based ReformCaught my eye — 1/26/24
Read more: Caught my eye — 1/26/24It has been fun to see the year really start to kick off this week with a bunch of policy releases. Shortages. Generic shortages are caused by a myriad of factors, but a big piece is the race to the bottom for prices. A fraction of a penny less and a contract shifts to another…
-
Another bite at the apple
Read more: Another bite at the appleIt used to be that pharmaceutical manufacturers had to worry (mostly) about federal health policy. Every few years manage through a big piece of legislation from Congress and then the regulation on Medicare, Medicaid, the Affordable Care Act and any regulation that came out of the legislation. But over the past few years, the drug…
Latest news
Categories
- 340B (35)
- Affordable Care Act (4)
- Alzheimer's (5)
- Biosimilars (21)
- Caught my eye (63)
- Cell and Gene (1)
- Chevron Deference (2)
- CMMI (11)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (32)
- Drug shortages (9)
- DTC (2)
- Employers (7)
- Generics (5)
- Health Equity (3)
- Healthcare Costs (28)
- ICER (10)
- Importation (2)
- Inflation Reduction Act (48)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (6)
- Medicare Advantage (16)
- Medicare Negotiation (50)
- Medicare Part D (46)
- Medicare Transaction Facilitator (3)
- Medicare Transaction Facilitator (8)
- Obesity (21)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (29)
- Reference Pricing (6)
- State-based Reform (15)
- Supply Chain (2)
- Uncategorized (6)
- Utilization Management (1)
- Vaccines (4)
- Value (13)